<DOC>
	<DOCNO>NCT00165854</DOCNO>
	<brief_summary>Part 1 : The primary purpose determine recommend dose E7070 combination capecitabine dose adjustment . Part 2 : The primary purpose determine safety efficacy combination patient metastatic CRC resistant 5-fluorouracil irinotecan .</brief_summary>
	<brief_title>Study E7070 Combined With Capecitabine Determine Efficacy Recommended Dose Combination Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Part 1 Histologically cytologically confirm solid tumour refractory standard therapy establish therapy exist Age &gt; = 18 year Karnofsky performance status &gt; = 70 % Life expectancy &gt; = 3 month Absolute neutrophil count &gt; = 1.5 × 109/l , platelet count ³ 100 × 109/l , haemoglobin level ³ 10 g/dl ( &gt; = 6.2 mmol/l ) ( prior transfusion permit ) Normal hepatic renal function define serum bilirubin £ 1.5 time upper limit normal , ALT AST £ 2.5 time upper limit normal ( £ 5 time upper limit normal presence hepatic metastasis ) , creatinine clearance ³ 50 ml/min ( CockroftGault formula ) Male female patient Written inform consent participate study Part 1 More two previous course document myelosuppresive chemotherapy ( epidermal growth factor target therapy constitute course chemotherapy ) CNS metastasis ( CT MRI scan do clinical suspicion CNS metastases ) Major surgery , chemotherapy radiation therapy ( except palliative ) within 4 week treatment start Previous investigational cytotoxic treatment malignant disease within 30 day start study Any treatment nononcological investigational drug within 30 day start study Pregnancy breast feeding ( woman childbearing potential must pregnancy test inclusion study ; postmenopausal woman must amenorrhoeic least 12 month ) . Female patient must use adequate contraceptive protection . Fertile male willing use contraception whose female partner use adequate contraceptive protection Uncontrolled infection Clinically significant cardiac impairment unstable ischaemic heart disease include myocardial infarction within three month study entry History alcoholism , drug addiction , psychiatric psychological condition opinion investigator would impair study compliance History hypersensitivity sulphonamides Prior severe unexpected reaction fluoropyrimidine therapy ( may explain dihydropyrimidine dehydrogenase deficiency hypersensitivity 5FU ) Malabsorption syndrome condition may affect absorption drug Concurrent previous malignancy different tumour type within five year start study except adequately treat nonmelanoma skin cancer cervical intraepithelial neoplasia Treatment within two week start study following : coumarin anticoagulant , terfenadine , cisapride , cyclosporin , tacrolimus , theophylline , diazepam , sulphonylurea hypoglycaemics , phenytoin , carbamazepine Legal incapacity Part 2 Ambulant patient progressive metastatic CRC receive prior treatment 5 FU irinotecan and/or oxaliplatin either single agent combination . Either 5 FU and/or irinotecan and/or oxaliplatin may administer adjuvant set treatment metastatic disease . Patients receive 5FU irinotecan oxaliplatin adjuvant setting must experience disease recurrence within one year start chemotherapy . At least one unidimensionally measurable lesion accord RECIST criterion Age ³ 18 year Karnofsky performance status ³ 70 % Life expectancy ³ 3 month Absolute neutrophil count ³ 1.5 × 109/l , platelet count ³ 100 × 109/l , haemoglobin level ³ 10 g/dl ( ³ 6.2 mmol/l ) ( prior transfusion permit ) Normal hepatic renal function define serum bilirubin £ 1.5 time upper limit normal , ALT AST £ 2.5 time upper limit normal ( £ 5 time upper limit normal presence hepatic metastasis ) , creatinine clearance ³ 50 ml/min ( CockroftGault formula ) Male female patient Written inform consent participate study Part 2 Prior chemotherapy 5FU , irinotecan and/or oxaliplatin CNS metastasis ( CT MRI scan do clinical suspicion CNS metastases ) Major surgery , chemotherapy radiation therapy ( except palliative ) within 4 week treatment start Previous investigational cytotoxic treatment malignant disease within 30 day start study Any treatment nononcological investigational drug within 30 day start study Pregnancy breast feeding ( woman childbearing potential must negative pregnancy test inclusion study ; postmenopausal woman must amenorrhoeic least 12 month ) . Female patient must use adequate contraceptive protection . Fertile male willing use contraception whose female partner use adequate contraceptive protection Uncontrolled infection Clinically significant cardiac impairment unstable ischaemic heart disease include myocardial infarction within three month study start History alcoholism , drug addiction , psychiatric psychological condition opinion investigator would impair study compliance History hypersensitivity sulphonamides Prior severe unexpected reaction fluoropyrimidine therapy ( may explain dihydropyrimidine dehydrogenase deficiency hypersensitivity 5FU ) Malabsorption syndrome condition may affect absorption drug Concurrent previous malignancy different tumour type within five year start study except adequately treat nonmelanoma skin cancer cervical intraepithelial neoplasia Treatment within two week start study following : coumarin anticoagulant , terfenadine , cisapride , cyclosporin , tacrolimus , theophylline , diazepam , sulphonylurea hypoglycaemics , phenytoin , carbamazepine Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>